Related Experiment Video

Updated: Jun 8, 2026

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers
09:36

Effect of Hyaluronic Acid 35 kDa on an In Vitro Model of Preterm Small Intestinal Injury and Healing Using Enteroid-Derived Monolayers

Published on: July 28, 2022

New treatments for infant colic

Francesco Savino1, Valentina Tarasco

  • 1Department of Pediatrics, Regina Margherita Children Hospital, University of Turin, Turin, Italy. francesco.savino@unito.it

Current Opinion in Pediatrics
|September 23, 2010
PubMed

Insights

Infantile colic, a common issue in newborns, may be linked to gut bacteria imbalances. Supplementing with Lactobacillus reuteri shows promise in reducing crying and abdominal pain in infants.

Area of Science:

  • Pediatrics
  • Gastroenterology
  • Microbiology

Background:

  • Infantile colic affects 3-month-old infants, causing parental distress.
  • Pathogenesis and treatment of infantile colic remain challenging despite extensive research.

Purpose of the Study:

  • Review recent studies on infantile colic interventions.
  • Explore new perspectives in infantile colic management.

Main Methods:

  • Literature review of recent studies on infantile colic interventions.
  • Analysis of research on the role of intestinal microbiota.

Main Results:

  • Infantile colic may be linked to intestinal microbiota composition, specifically low lactobacilli and high coliforms.
  • Lactobacillus reuteri supplementation shows benefits, potentially by influencing gut motility and pain perception.

Conclusions:

  • Infantile colic has varied presentations; rule out underlying conditions first.
  • Well-tolerated strategies are recommended, with potential for new research and treatments targeting abdominal pain.
Abstract

More Related Videos

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation09:02

Breast Milk Enhances Growth of Enteroids: An Ex Vivo Model of Cell Proliferation

Published on: February 15, 2018

Electrophysiological Measurements and Analysis of Nociception in Human Infants09:18

Electrophysiological Measurements and Analysis of Nociception in Human Infants

Published on: December 20, 2011

Related Concept Videos

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Irritable Bowel Syndrome III: Medical and Nursing Management01:30

Irritable Bowel Syndrome III: Medical and Nursing Management

Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD: